Yahoo · Sep 18, 2026
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes"). The offering size was increased from the previously announced offering size of $1.05 billion aggregate principal amount of notes. The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $200 million aggregate principal amount of the Convertib
